Successful kinase bypass with new acyclovir phosphoramidate prodrugs

Bioorganic & Medicinal Chemistry Letters
2008.0

Abstract

Novel phosphoramidates of acyclovir have been prepared and evaluated in vitro against acyclovir-sensitive and -resistant herpes simplex virus (HSV) types 1 and 2 and varicella-zoster virus (VZV). Unlike the parent nucleoside these novel phosphate prodrugs retain antiviral potency versus the ACV-resistant virus strain, suggesting an efficient bypass of the viral thymidine kinase.

Knowledge Graph

Similar Paper